









Markets
/
Stocks
/
nasdaq-xncr
/

Xencor Inc

XNCR

11.420USD

-0.890-7.23%

Close 03/27, 16:00（ET）Quotes delayed by 15 min

312.82MMarket Cap

LossP/E TTM



Xencor Inc

11.420

-0.890-7.23%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Xencor Inc

Currency: USD Updated: 2026-03-27

Key Insights

Xencor Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 52 out of 391 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 28.36.In the medium term, the stock price is expected to trend down.Despite a weak stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Xencor Inc's Score

Industry at a Glance

Industry Ranking

52 / 391

Overall Ranking

157 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Xencor Inc Highlights

StrengthsRisks

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases. It has more than 20 candidates engineered with its XmAb technology that are in clinical development, and multiple XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly-owned development candidates include XmAb942, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Its clinical-stage drug candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, Xpro1595, Obexelimab, and Novartis XmAb, an undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of efbalropendekin alfa (XmAb306/RG6323). Its Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

Fairly Valued

The company’s latest PE is -9.22, at a medium 3-year percentile range.

Held by Invesco

Star Investor Invesco holds 207.49K shares of this stock.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

28.359

Target Price

+130.37%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-27

The current financial score of Xencor Inc is 6.08, ranking 291 out of 391 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 28.24M, representing a year-over-year decrease of 59.67%, while its net profit experienced a year-over-year decrease of 87.56%.

Score

Industry at a Glance

Previous score

6.08

Change



Financials

5.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

10.00

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.72

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

5.21

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.11

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Xencor Inc's Company Valuation

Currency: USD Updated: 2026-03-27

The current valuation score of Xencor Inc is 7.12, ranking 167 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -9.22, which is -73.13% below the recent high of -2.48 and -333.09% above the recent low of -39.94.

Score

Industry at a Glance

Previous score

7.12

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 52/391

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-27

The current earnings forecast score of Xencor Inc is 8.43, ranking 126 out of 391 in the Biotechnology & Medical Research industry. The average price target is 27.00, with a high of 42.00 and a low of 17.00.

Score

Industry at a Glance

Previous score

8.43

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 14 analysts

Buy

Current Rating

28.359

Target Price

+130.37%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

548

Total

Median

Average

Company name

Ratings

Analysts

Xencor Inc

XNCR

CRISPR Therapeutics AG

CRSP

IQVIA Holdings Inc

IQV

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

Beigene Ltd

ONC

...

110

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-27

The current price momentum score of Xencor Inc is 6.94, ranking 107 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 12.94 and the support level at 10.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

7.44

Change

-0.5

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(3)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

0.054

Neutral

RSI(14)

43.407

Neutral

STOCH(KDJ)(9,3,3)

45.974

Sell

ATR(14)

0.744

High Vlolatility

CCI(14)

-74.811

Neutral

Williams %R

78.652

Sell

TRIX(12,20)

-0.022

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

12.014

Sell

MA10

11.968

Sell

MA20

11.936

Sell

MA50

12.095

Sell

MA100

13.815

Sell

MA200

11.787

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Xencor Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 119.03%, representing a quarter-over-quarter increase of 0.83%. The largest institutional shareholder is PRIMECAP Management, holding a total of 10.22M shares, representing 13.93% of shares outstanding, with 1.59% increase in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

10.58M

-0.87%

PRIMECAP Management Company

Star Investors

10.68M

+1.40%

The Vanguard Group, Inc.

Star Investors

7.17M

+1.14%

BVF Partners L.P.

4.62M

+68.58%

RTW Investments L.P.

6.22M

+158.90%

State Street Investment Management (US)

3.67M

-3.77%

EcoR1 Capital, LLC

6.14M

TCG Crossover Management, LLC

2.45M

Geode Capital Management, L.L.C.

1.73M

+1.48%

T. Rowe Price Associates, Inc.

Star Investors

1.57M

-56.89%

Risk Assessment

Currency: USD Updated: 2026-03-27

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Xencor Inc is 4.62, ranking 75 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.99. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Xencor Inc’s latest ESG disclosure leads the Biotechnology & Medical Research industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.